Akari Therapeutics consolidates remaining private placement closings, issues 980,395 ADSs

Akari Therapeutics Plc

Combined second and third closings into single closing on June 26, 2026; issued 980,395 ADSs (or prefunded warrants).
First closing of 490,193 ADSs occurred May 27, 2026, under the original three-tranche structure.
Delivery of Series H, I, and J warrants contingent on shareholder approval at June 30, 2026 annual meeting.
No other changes to the securities purchase agreement besides consolidation of closings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.